胰高血糖素样肽-1受体激动剂在青少年肥胖中应用的研究进展  

Research progress on the application of glucagon-like peptide-1 receptor agonist in adolescent obesity

作　　者：艾荣杰 杨焱[1] 徐轶明 赵明[2] AI Rongjie;YANG Yan;XU Yiming;ZHAO Ming(General Medical Department,Affiliated Hospital of Inner Mongolia Minzu University,Inner Mongolia,Tongliao 028000,China;Cardiovascular Medicine,Affiliated Hospital of Inner Mongolia Minzu University,Inner Mongolia,Tongliao 028000,China)

机构地区：[1]内蒙古民族大学附属医院全科医疗科,内蒙古通辽028000 [2]内蒙古民族大学附属医院心血管内科,内蒙古通辽028000

出　　处：《中国医药科学》2025年第4期44-48,共5页China Medicine And Pharmacy

摘　　要：青少年肥胖日益成为严峻的公共卫生问题,并且使其成年后患高血压、心血管疾病及2型糖尿病的风险增加。由于肥胖的严重危害,迫切需要有效的治疗方法,目前对肥胖的主要干预措施是生活方式干预,但在青少年肥胖者的治疗中效果不佳,只有极少部分严重肥胖的患者能够仅通过生活方式干预实现并维持临床上显著的体重减轻。胰高血糖素样肽-1受体激动剂(GLP-1RA)是一种胰高血糖素样肽-1类似物,可通过发挥降低食欲和延缓胃排空的作用来诱导体重减轻,改善饮食控制并减少能量摄入。GLP-1RA已被用于超重与肥胖成人的长期体重管理,未来在治疗青少年肥胖者中将有着广阔的应用前景。本文讨论了GLP-1RA在青少年肥胖中的临床应用进展。Adolescent obesity has increasingly become a serious public health problem,and it increases the risk of hypertension,cardiovascular disease and type 2 diabetes mellitus in adulthood.Due to the serious harm of obesity,effective treatment methods are urgently needed.At present,lifestyle intervention is the main intervention measure for obesity,but the effect is not good in the treatment of adolescent obesity.Only a few severely obese patients can achieve and maintain clinically significant weight loss only through lifestyle intervention.Glucagonlike peptide-1 receptor agonist(GLP-1RA)is an analogue of glucagon-like peptide-1,which can reduce appetite and gastric emptying to induce weight loss,improve diet control and reduce energy intake.GLP-1RA has been used for long-term weight management of overweight and obese adults,and it will have a broad application prospect in the treatment of adolescent obesity in the future.T his paper discusses the clinical application progres s of GLP-1 receptor agonist in obese adolescents.

关 键 词：胰高血糖素样肽-1受体激动剂 青少年 肥胖 减重 

分 类 号：R723.14[医药卫生—儿科]